ELIAS Animal Health Reports Results from the (ECI-OSA-04) Study of ELIAS Cancer Immunotherapy (ECI) for Treating Bone Cancer in Dogs
Shots:
- The USDA has agreed that the data found from the company's (ECI-OSA-04) study of ELIAS Cancer Immunotherapy (ECI) indicates a reasonable expectation of efficacy
- The (ECI-OSA-04) study evaluated the safety and efficacy of ECI in 100 patients for canine cancer. The ECI conditions the immune system to identify the patient's unique cancer and deploys activated killer T cells to target the cancer cells
- Additionally, the company anticipates securing a $10M Series A funding for manufacturing expansion, ECI product launch & advancing its product pipeline incl. a novel oncolytic immunotx., a pilot study of ECI + checkpoint inhibitor and assessing adoptive cell therapy in dogs using a non-amputation surgical technique
Ref: ELIAS Animal Health | Image: ELIAS Animal Health
Related News:- Merck Animal Health Reports Updates from the Study Assessing the Mental Health and Well-Being of US Veterinarians
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
